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Abstract
Functional data analysis is an important area in modern statistics and has been successfully
applied in many fields. Although many scientific studies aim to find causations, a predominant
majority of functional data analysis approaches can only reveal correlations. In this paper,
average treatment effect estimation is studied for observational data with functional covariates.
This paper generalizes various state-of-art propensity score estimation methods for multivariate
data to functional data. The resulting average treatment effect estimators via propensity score
weighting are numerically evaluated by a simulation study and applied to a real-world dataset
to study the causal effect of duloxitine on the pain relief of chronic knee osteoarthritis patients.
Keywords: Functional principal component analysis; Functional regression; Direct modeling; Co-
variate balancing; Magnetic resonance imaging.
1 Introduction
Functional data analysis (FDA) has become increasingly important in modern statistics and has
been successfully applied in a variety of scientific fields. Apart from books on general introductions
to FDA (e.g., Bosq, 2000; Ferraty and Vieu, 2006; Horva´th and Kokoszka, 2012; Hsing and Eubank,
2015; Kokoszka and Reimherr, 2017; Ramsay and Silverman, 2005), recent advances of FDA, in-
cluding innovative methodologies, profound theories, efficient algorithms, and successful applica-
tions, have been illustrated by numerous survey papers (e.g., Chen et al., 2017; Cuevas, 2014;
Delicado et al., 2010; Geenens, 2011; Guo, 2004; Ho¨rmann and Kokoszka, 2012; Kokoszka and Reimherr,
2019; Marron and Alonso, 2014; Mu¨ller, 2008; Nagy, 2017; Shang, 2014; Vieu, 2018; Wang et al.,
2016).
A majority of FDA methods can only reveal correlations primarily via either functional regres-
sion models (for reviews see e.g., Greven and Scheipl, 2017; Morris, 2015; Paganoni and Sangalli,
2017; Reiss et al., 2017) or correlation measures (e.g., Cupidon et al., 2008; Dubin and Mu¨ller, 2005;
Eubank and Hsing, 2008; Leurgans et al., 1993; Lian, 2014; Shin and Lee, 2015; Zhou et al., 2018).
However, FDA methods for causal inference is underdeveloped despite the importance of causation
in many scientific studies. Among very few exceptions, almost all of them focus on random-
ized clinical trials (e.g., Ciarleglio et al., 2015, 2018; Lindquist, 2012; McKeague and Qian, 2014;
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Zhao and Luo, 2019; Zhao et al., 2018). In classical causal inference for observational studies where
multivariate data are of primary interest, the propensity score (Rosenbaum and Rubin, 1983) plays
an important role and has been widely applied in epidemiology and political science among others.
Despite its popularity, its use in FDA to study causations in observational studies is nearly void.
The main contribution of this paper is to introduce and adapt various state-of-art propensity
score methods to observational functional data. We consider the scenario where the treatment is
binary and at least one covariate is functional. We generalize the definition of the propensity score
to functional data, and study two types of propensity score estimations. The propensity score is
estimated by either directly fitting a functional regression model or balancing appropriate functions
of the covariates. This paper in particular focuses on propensity score weighting (e.g., Hirano et al.,
2003; Robins et al., 2000; Rosenbaum, 1987), although the propensity score may be used to adjust
for confounding through other means, e.g., matching (e.g., Abadie and Imbens, 2006; Rosenbaum,
1989; Rosenbaum and Rubin, 1985) and subclassification (e.g., Hansen, 2004; Rosenbaum, 1991;
Rosenbaum and Rubin, 1984). A systematic comparison of two popular propensity-score-weighted
average treatment effect estimators is provided in both a simulation study and a real data applica-
tion.
The rest of the paper proceeds as follows. Section 2 provides the problem setup and generalizes
the classical definition of the propensity score to functional data where the treatment is binary
and one covariate is functional. Section 3 introduces two types of propensity score estimations
via direct modeling and covariate balancing respectively and two widely used average treatment
effect estimators via propensity score weighting. The two average treatment effect estimators based
on a variety of estimated propensity score weights are comprehensively compared in a simulation
study in Section 4. They are also applied in a real data analysis in Section 5 to study the causal
effect of duloxitine on the pain relief of chronic knee osteoarthritis patients. Discussion in Section
6 concludes the paper.
2 Framework
Suppose that Y is a continuous outcome, T is a binary treatment variable which equals either 0
(control) or 1 (treatment), W is a multivariate covariate, and X(·) is a functional covariate defined
on a compact domain T . Suppose that E ∫
T
{X(t)}2 dt < ∞ and X(·) is smooth, e.g., continuous
or twice-differentiable. Without loss of generality E(W) = 0, T = [0, 1] and E{X(t)} = 0 for all
t ∈ [0, 1].
Let Y (1) and Y (0) represent the potential values of Y when T = 1 and 0 respectively. In
practice Y = TY (1) + (1 − T )Y (0) is observable but Y (1) and Y (0) are not both observable.
Based on {(Yi, Ti,Wi, {Xi(t) : t ∈ [0, 1]}) : i = 1, . . . , n}, which are independently and identically
distributed (i.i.d.) copies of (Y, T,W, {X(t) : t ∈ [0, 1]}), we aim to estimate the average treatment
effect τ = E{Y (1)− Y (0)}.
We assume that each Xi(·) is fully observed, but the methods below are also applicable for
densely measured Xi(·) since its entire trajectory can be accurately recovered by smoothing (e.g.,
Zhang and Chen, 2007). In this paper we only consider low-dimensional Wi. The handling of high-
dimensional multivariate covariates is beyond the scope of this paper but is a promising topic for
future research (e.g., Belloni et al., 2017, 2014; Chernozhukov et al., 2018; Farrell, 2015; Ning et al.,
2018).
Similar to its classical counterpart (e.g., Robins et al., 2000; Rosenbaum and Rubin, 1983), the
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propensity score is defined by
p(Wi,Xi) = P (Ti = 1 |Wi,Xi(·)). (1)
In this paper we make the following two assumptions:
Assumption 1.
Ti ⊥ (Yi(0), Yi(1)) | (Wi,Xi(·)) ,
where “⊥” represents independence.
Assumption 2. The propensity score satisfies
0 < P (Ti = 1 |Wi = w,Xi(·) = x(·)) < 1,
for all vectors w and all functions x(·) defined on [0, 1] such that ∫ 1
0
{x(t)}2 dt <∞ .
Assumptions 1 and 2 are straightforward generalizations of the commonly used strong ignor-
ability and positivity assumptions in classical causal inference respectively. Assumption 1 implies
that there is no unmeasured covariate, while Assumption 2 essentially requires that every sample
has a positive probability of receiving the treatment or being in the control group.
3 Methodology
In this section, we introduce various methods for propensity score estimation and two average
treatment effect estimators via propensity score weighting.
3.1 Propensity Score Estimation
We propose two types of propensity score estimations, one via direct modeling and the other
via covariate balancing. They will be introduced in Sections 3.1.1 and 3.1.2 respectively.
3.1.1 Direct Modeling
To estimate the propensity score p(Wi,Xi), one may assume a parametric model for p(Wi,Xi)
and fit it with an appropriate estimation procedure.
The simplest model might be the generalized functional partial linear model (GFPLM):
logit {p(Wi,Xi)} = α0 +α⊤1 Wi +
∫ 1
0
β(t)Xi(t) dt, (2)
where logit(x) = log{x/(1−x)} and the scalar α0, vector α1 and function β(·) are unknown parame-
ters to be estimated. Apparently the GFPLM is an extension of James (2002), Mu¨ller and Stadtmu¨ller
(2005) and Shin (2009).
Similar to fitting other functional regression models considered in the FDA literature, regu-
larization for the functional coefficient β is needed to fit (2). Popular regularizations include the
truncated basis function expansion (e.g., Cardot et al., 1999; Ramsay and Silverman, 2005, Ch.4),
roughness penalization (e.g., Yuan and Cai, 2010) and their combinations (e.g., Cardot et al.,
2003; Ramsay and Silverman, 2005, Ch.5). The most straightforward regularization is perhaps the
first one above where the basis functions are obtained by functional principal component analysis
(FPCA). Explicitly, the functional covariate may be approximated by by Xi(t) ≈
∑
L
k=1Aikφk(t)
where φk(·), 1 ≤ k ≤ L < ∞, are eigenfunctions corresponding to the top L eigenvalues λ1 ≥
3
· · · ≥ λL > 0 of the covariance function Cov{X(s),X(t)}, and Aik =
∫ 1
0
Xi(t)φk(t), 1 ≤ k ≤ L, are
corresponding FPC scores. Thus
logit {p(Wi,Xi)} ≈ α0 +α⊤1 Wi +
L∑
k=1
βkAik, (3)
where βk =
∫ 1
0
β(t)φk(t) dt, 1 ≤ k ≤ L. The maximum likelihood method can be used to find the
parameter estimates (αˆ0, αˆ1, βˆ1, . . . , βˆL) and thus the propensity score estimate pˆ(Wi,Xi).
Remark 1.
1. The terms φk(·), λk, Aik, k ≥ 1 above are all population quantities. In practice one can only
obtain their sample versions.
2. The aforementioned FPCA-regularized maximum likelihood method is also applicable to fit a
GPFLM if Xi is a multidimensional functional covariate, i.e.,
logit {p(Wi,Xi)} = α0 +α⊤1 Wi +
∫
β(u)Xi(u) du,
where u is a generic and multidimensional index for Xi. With the FPC scores obtained by FPCA,
this multidimensional GPFLM can also be approximated by (3) and fitted by the maximum likelihood
method.
3. Following the suggestion by Rubin (2007) that the propensity score estimation is conducted
without access to outcome data, the number of FPC scores L, a tuning parameter, can be determined
by various means when estimating the propensity score, including the fraction of variation explained
(e.g., 95% or 99%), cross-validation, the Akaike information criterion (AIC), etc.
In addition to the GFPLM, one may fit other propensity score models, such as the functional
generalized additive model (FGAM, e.g., McLean et al., 2014; Mu¨ller et al., 2013):
logit {p(Wi,Xi)} = α0 +α⊤1 Wi +
∫ 1
0
η(t,Xi(t)) dt, (4)
where the unknown parameters are α0, a scalar, α1, a vector, and η(∗, ·), a bivariate function. To
fit (4), one may apply the maximum likelihood method after approximating η(∗, ·) by a set of tensor
products of B-spline basis functions.
3.1.2 Covariate Balancing
In the classical literature on causal inference, it is well known that parametric methods for
propensity score estimation may suffer from model misspecification substantially (e.g., Kang and Schafer,
2007; Smith and Todd, 2005). Recently covariate balancing methods, which aim to mimic random-
ization, have been proposed as important alternatives (e.g., Hainmueller, 2012; Imai and Ratkovic,
2014; Li et al., 2018; Qin and Zhang, 2007; Wong and Chan, 2018; Zhao, 2019; Zubizarreta, 2015).
To the best of our knowledge, all existing covariate balancing methods so far are developed to
handle multivariate covariates and cannot be directly used for functional covariates.
One way of balancing both multivariate covariates Wi and functional covariate Xi is to gen-
eralize the covariate balancing propensity score (CBPS) method (Imai and Ratkovic, 2014) by
considering the following functional covariate balancing equation:
1
n
n∑
i=1
{
Ti
p(Wi,Xi)
− (1− Ti)
1− p(Wi,Xi)
}
h(Wi,Xi) = 0, (5)
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where a parametric model is assumed for the propensity score p(Wi,Xi) and h(Wi,Xi) is a user-
defined vector-valued function to reflect how Wi and Xi are balanced.
To solve (5), we propose to substitute the functional covariate Xi by a multivariate covariate.
For example, by FPCA as in Section 3.1.1, the functional covariate Xi(·) can be approximated
by Xi(t) ≈
∑
L
k=1Aikφk(t) with a proper integer L such that Ai = (Ai1, . . . , AiL)
⊤ possesses a
majority of the information of Xi. Thus Ai may be used as a substitute of Xi and we may replace
p(Wi,Xi) and h(Wi,Xi) in (5) by the substitute propensity score
p(Ci) = P (Ti = 1 | Ci), (6)
and another user-defined vector-valued function h(Ci) respectively, where Ci = (W
⊤
i
,A⊤
i
)⊤. Ob-
viously if X(·) is of finite rank in terms of its spectral decomposition, i.e., FPCA, the substitute
propensity score p(Ci) is equivalent to p(Wi,Xi) when L is chosen to be the rank of X(·). Then
it suffices to solve
1
n
n∑
i=1
{
Ti
p(Ci)
− (1− Ti)
1− p(Ci)
}
h(Ci) = 0, (7)
which is exactly the covariate balancing equation for multivariate covariates (Imai and Ratkovic,
2014).
To solve (7), one may assume a logistic model for p(Ci):
logit {p(Ci)} = γ0 + γ⊤1 Ci, (8)
where γ0 and γ1 are unknown parameters to be estimated, which is equivalent to the approximate
GFPLM in (3). One also needs to specify h(Ci) to reflect how Ci are balanced. For example, one
may define h(Ci) = Ci to balance the first moment of Ci. Alternatively to balance both the first
and second moments of Ci, one may use h(Ci) = (C
⊤
i
, (C2
i
)⊤)⊤ where C2
i
contains the entry-wise
square of Ci. Then we let pˆ(Wi,Xi) = pˆ(Ci) obtained in (7).
3.2 Average Treatment Effect Estimation
To estimate the average treatment effect τ = E{Y (1)−Y (0)}, a variety of estimators via propen-
sity score weighting have been proposed, such as the Horvitz-Thompson estimator (Horvitz and Thompson,
1952), the inverse propensity score weighting estimator (Hirano et al., 2003), the weighted least
squares regression estimator (Freedman and Berk, 2008; Robins et al., 2000), and the doubly ro-
bust estimator (Robins et al., 1994) among others.
In the simulation experiments and real data application below, we will consider two repre-
sentative average treatment effect estimators, the Horvitz-Thompson (HT) estimator and Ha´jek
estimator, to numerically evaluate and compare the propensity score estimation methods in Sec-
tion 3.1.
Explicitly, for each propensity score estimate pˆi = pˆ(Wi,Xi) obtained by either direct modeling
or covariate balancing approach, the HT and Ha´jek estimators are respectively defined by
τˆHT =
1
n
n∑
i=1
{
TiYi
pˆi
− (1− Ti)Yi
1− pˆi
}
, and
τˆHa´jek =
∑
n
i=1 TiYi/pˆi∑
n
i=1 Ti/pˆi
−
∑
n
i=1(1− Ti)Yi/(1− pˆi)∑
n
i=1(1− Ti)/(1 − pˆi)
.
Apparently the Ha´jek estimator, which normalizes the HT estimator, is a special inverse propensity
score weighting estimator.
5
4 Simulation
In this section we present a simulation study to evaluate and compare a few propensity score
estimation methods in terms of the performances of their resulting average treatment effect esti-
mations.
We had 1, 000 simulation runs where we generated independent subjects with sample size n =
200 and 500 respectively. For the ith subject, Zi1, . . . , Zi6 were i.i.d. sampled from the standard
normal distribution. The multivariate covariate Wi = (Wi1,Wi2,Wi3)
⊤ was generated by Wi1 =
Zi1+2Zi2, Wi2 = Z
2
i2−Z2i3, Wi3 = exp(Zi3)− exp(1/2). The functional covariate was generated by
Xi(t) =
∑6
k=1Aikφk(t), t ∈ [0, 1] where Aik = 2Zik/k, k = 1, . . . , 6, and φ2k−1(t) =
√
2 cos(2pikt),
φ2k(t) =
√
2 sin(2pikt), k = 1, 2, 3. Note that E(Wi) = 0 and E{Xi(t)} = 0, t ∈ [0, 1].
We generated the treatment Ti using the three propensity score models (PSMs) for p(Wi,Xi)
as follows.
1. PSM 1: The treatment Ti follows a Bernoulli distribution with the probability
p(Wi,Xi) =
exp{α⊤Wi +
∫ 1
0
β0(t)Xi(t)}
1 + exp{α⊤Wi +
∫ 1
0
β0(t)Xi(t)}
,
where α = (−1, 0.5,−0.1)⊤ and β0(t) = 2φ1(t) + 0.5φ2(t) + 0.5φ3(t) + φ4(t).
2. PSM 2: The treatment Ti follows a Bernoulli distribution with the probability
p(Wi,Xi) =
exp{α⊤Wi +
∫ 1
0
η0(t,Xi(t)) dt}
1 + exp{α⊤Wi +
∫ 1
0
η0(t,Xi(t)) dt}
,
where α = (−1, 0.5,−0.1)⊤ and η0(t, x) = −0.5 + exp[−{(t− 0.5)/0.3}2 − (x/5)2].
3. PSM 3: The treatment Ti follows a Bernoulli distribution with the probability
p(Wi,Xi) =
exp(−Zi1 + 0.5Zi2 − 0.25Zi3 − 0.1Zi4)
1 + exp(−Zi1 + 0.5Zi2 − 0.25Zi3 − 0.1Zi4) .
Obviously PSM 1 is a GFPLM as in (2) and PSM 2 is an FGAM as in (4).
We generated the outcome Yi based on the following two outcome models (OMs).
1. OM 1: Yi = 200 + 10Ti + (1.5Ti − 0.5)(27.4Zi1 + 13.7Zi2 + 13.7Zi3 + 13.7Zi4) + ei where ei
is generated from the standard normal distribution independently of Zi1, . . . , Zi6. The true
average treatment effect is τ = 10.
2. OM 2: Yi = Zi1Z
3
i2Z
2
i3Zi4 + ei where ei follows the standard normal distribution which is
independent of Zi1, . . . , Zi6. The true average treatment effect is τ = 0.
We compared the performances of five propensity score estimation methods in the simulation
study, denoted by GFPLM, FGAM, CBPS1, CBPS2 and KBCB respectively. The first two methods
are via direct modeling while the last three are via covariate balancing. By the FPCA approximation
and maximum likelihood method as in Section 3.1.1, GFPLM fits (2) to estimate the propensity
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score. The number of FPC scores L was selected as the smallest integer such that the fraction
of variation explained by the top L FPC scores is at least 95%. FGAM obtains the propensity
score estimate by fitting (4) directly, where tensor products of seven cubic B-spline basis functions
were used to approximate η(∗, ·) before the maximum likelihood method was applied. Apparently
GFPLM is subject to model misspecification when data are generated from PSM 2, while both
GFPLM and FGAM fit incorrect models when data are generated from PSM 3.
Both CBPS1 and CBPS2 are based on the CBPS method as introduced in Section 3.1.2. The
multivariate substituteAi = (Ai1, . . . , AiL)
⊤ for the functional covariate Xi was obtained by FPCA
which explains at least 95% of the variation of Xi, and (8) was assumed for the substitute propen-
sity score p(Ci). CBPS1 balanced the first moments of Ci while CBPS2 balanced both first and
second moments of Ci, and they were performed using the CBPS R package. KBCB is another
covariate functional balancing method recently proposed by Wong and Chan (2018), which controls
the balance of Ci over a reproducing kernel Hilbert space (RKHS). KBCB was implemented using
the ATE.ncb R package downloaded from https://github.com/raymondkww/ATE.ncb where the
RKHS was chosen as the second-order Sobolev space.
Table 1: Bias and RMSE values for the HT and Ha´jek estimates based on five propensity score estimation
methods for PSM 1 and OM 1. The percentages beside a propensity score estimation method, if any, refer
to the proportions of simulation runs used to calculate the bias and RMSE values for the HT and Ha´jek
estimates respectively, and “-” denotes 100%. All simulation runs were used for a propensity score estimation
method if no such percentages are given.
HT Ha´jek
Bias RMSE Bias RMSE
n = 200
GFPLM (99.9%, -) 4.82 100.17 2.28 11.28
FGAM (99.9%, -) 8.44 17.12 9.58 10.47
CBPS1 2.90 45.87 3.00 9.15
CBPS2 (99.8%, -) 1.77 28.58 3.75 7.29
KBCB 1.69 4.43 2.08 4.58
n = 500
GFPLM 1.78 75.83 1.65 10.07
FGAM 9.02 11.98 9.56 9.86
CBPS1 2.47 39.25 2.27 7.58
CBPS2 (99.8%, -) 1.98 21.26 2.73 5.74
KBCB 0.79 2.56 0.96 2.62
With the propensity score estimate obtained by each of the five methods above, we achieved
the HT and Ha´jek estimates for the average treatment effect, i.e., τˆHT and τˆHa´jek as in Section 3.2.
Note that KBCB does not give an estimate for the substitute propensity score p(Ci). Instead it
provides estimates for both Ti/p(Ci) and (1− Ti)/{1− p(Ci)}, but they suffice to obtain both HT
and Ha´jek estimates.
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Table 2: The same as Table 1 except for PSM 2 and OM 1.
HT Ha´jek
Bias RMSE Bias RMSE
n = 200
GFPLM (99.9%, -) 1.26 57.49 -0.68 8.20
FGAM (99.8%, -) -1.05 59.70 -0.93 8.22
CBPS1 -1.22 29.65 -1.44 6.48
CBPS2 (99.9%, -) -4.19 22.22 -1.81 5.62
KBCB -1.03 4.11 -0.49 3.95
n = 500
GFPLM -2.46 40.28 -0.87 6.00
FGAM -3.23 43.39 -0.74 5.95
CBPS1 -0.38 22.52 -1.14 4.94
CBPS2 -0.98 15.31 -0.98 3.83
KBCB -0.35 2.53 -0.17 2.51
The bias and root mean squared error (RMSE) values for the HT and Ha´jek estimates are
given in Tables 1–6. For each average treatment effect estimate based on any propensity score
estimation method, we removed the simulation runs of which average treatment effect estimates
are ten standard deviations away from the mean, and used the remaining simulated data to calculate
bias and RMSE values.
Table 3: The same as Table 1 except for PSM 3 and OM 1.
HT Ha´jek
Bias RMSE Bias RMSE
n = 200
GFPLM (99.9%, -) 0.15 22.19 -0.15 5.66
FGAM (99.9%, -) -4.22 9.16 -4.37 5.96
CBPS1 -1.83 13.02 -1.14 4.63
CBPS2 (99.8%, -) -1.69 14.80 -1.11 4.83
KBCB -0.37 3.92 -0.27 3.90
n=500
GFPLM -0.04 12.51 -0.09 3.45
FGAM -4.03 5.84 -4.37 5.05
CBPS1 -0.63 9.12 -0.70 3.06
CBPS2 -1.27 8.40 -0.81 2.91
KBCB -0.07 2.46 -0.05 2.46
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Table 4: The same as Table 1 except for PSM 1 and OM 2. All bias and RMSE values are given in the unit
of 10−1.
10−1
HT Ha´jek
Bias RMSE Bias RMSE
n = 200
GFPLM (99.9%, 99.8%) 0.05 18.26 0.27 12.48
FGAM (99.9%, 99.9%) 3.28 11.83 3.29 11.75
CBPS1 (99.9%, 99.9%) 0.59 9.74 0.65 10.71
CBPS2 (99.8%, -) 0.99 7.92 1.04 8.26
KBCB 0.95 8.70 0.95 8.71
n = 500
GFPLM (99.8%, 99.9%) -0.07 11.59 -0.04 10.76
FGAM (99.8%, 99.8%) 4.01 10.40 4.02 10.43
CBPS1 (99.9%, 99.9%) 0.11 8.49 0.22 8.63
CBPS2 (99.8%, 99.9%) 0.51 6.74 0.64 6.58
KBCB 1.04 6.71 1.04 6.71
The six tables show that for any propensity score estimation methods but KBCB, a larger sample
size generally improves the average treatment effect estimation accuracy measured by RMSE, but
it unnecessarily improves the bias. With respect to RMSE, the three covariate balancing methods
are generally better than the two directly modeling methods, although FGAM occasionally outper-
forms the two CBPS methods (see Tables 1 and 3). Between the two direct modeling methods,
FGAM almost always performs better than GFPLM in terms of RMSE even when the latter cor-
rectly specifies PSM 1, but the former is often worse in terms of bias. The results for the two
CBPS methods indicate that balancing additional covariate moments can typically improve average
treatment effect estimation. Among all five propensity score estimation methods, KBCB performs
overall the best in terms of both bias and RMSE with the only exceptions for PSM 1 and OM 2
(see Table 4) and for PSM 2 and OM 2 with n = 200 (see Table 5).
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Table 5: The same as Table 4 except for PSM 2 and OM 2.
10−1
HT Ha´jek
Bias RMSE Bias RMSE
n = 200
GFPLM (99.8%, 99.8%) -0.54 10.24 -0.52 9.29
FGAM (99.7%, 99.9%) -0.21 10.17 -0.24 9.91
CBPS1 -0.50 8.43 -0.51 8.87
CBPS2 (99.9%, -) -0.35 5.95 -0.34 6.70
KBCB -0.66 7.13 -0.66 7.14
n = 500
GFPLM (99.8%, 99.9%) -0.53 8.46 -0.54 8.25
FGAM (99.8%, 99.9%) -0.54 9.70 -0.55 8.96
CBPS1 -0.62 6.86 -0.67 7.17
CBPS2 (99.9%, 99.9%) -0.55 6.24 -0.60 6.35
KBCB -0.60 5.12 -0.60 5.12
Table 6: The same as Table 4 except for PSM 3 and OM 2.
10−1
HT Ha´jek
Bias RMSE Bias RMSE
n = 200
GFPLM (99.9%, 99.9%) -0.43 10.91 -0.39 10.49
FGAM (99.8%, 99.8%) -0.29 10.19 -0.30 10.31
CBPS1 -0.35 8.43 -0.37 8.75
CBPS2 (99.9%, 99.9%) -0.37 10.43 -0.31 8.94
KBCB -0.12 7.10 -0.12 7.11
n = 500
GFPLM -0.92 7.44 -0.90 7.35
FGAM -1.12 7.91 -1.13 7.92
CBPS1 -0.70 6.29 -0.72 6.42
CBPS2 (99.9%, 99.9%) -0.59 5.89 -0.60 6.04
KBCB -0.30 4.88 -0.30 4.88
In terms of computational stability, all propensity score estimation methods perform satisfacto-
rily, but KBCB is the most robust method since it never produces outlying average treatment effect
estimates. CBPS1 is slightly less likely to produce extreme average treatment effect estimates than
CBPS2. This is somewhat unsurprising since the latter additionally balances the second moments of
covariates. Compare to the HT estimates, the Ha´jek estimates generally have fewer outlying values
and smaller RMSE values for all propensity score estimation methods but KBCB. This observation
demonstrates the benefit of inverse propensity score weighting.
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5 Data Application
We applied three propensity score weighting methods introduced above to a pain relief dataset
(Te´treault et al., 2016), which was downloaded from OpenNeuro (https://openneuro.org/datasets/ds000208/versions/1.0.0).
The dataset consists of 56 chronic knee osteoarthritis pain patients in two separate clinical trials.
The first trial was single-blind where all 17 subjects took placebo pills, while the second trial
was double-blind where 39 subjects were randomized to take either duloxetine (30/60mg QD) or
placebo. With the observational data obtained by combining the two trials, we aimed to estimate
the average treatment effect of duloxitine compared to placebos on chronic knee osteoarthritis pain
relief. The pain relief was measured by the visual analog scale (VAS) score, and the Western On-
tario and McMaster Universities Osteoarthritis Index (WOMAC) score, and we studied the average
duloxitine effect on both measures separately.
Table 7: The HT and Ha´jek estimates for the average treatment effect of duloxitine on pain relief measured
by the VAS score. Bootstrap standard errors (SE) and 95% bootstrap percentile confidence intervals were
obtained by 1,000 bootstrap samples.
τˆ SE [2.5% , 97.5%]
HT
GFPLM -5.99 11.62 [-22.77 , 6.49]
CBPS -5.26 4.12 [-12.21 , 3.17]
KBCB 0.39 3.43 [-6.29 , 7.21]
Ha´jek
GFPLM -0.52 4.27 [-9.04 , 7.58]
CBPS -0.23 3.64 [-6.87 , 7.18]
KBCB 0.28 3.37 [-6.14 , 7.17]
A subject is considered to receive the treatment if he/she took duloxitine; those who took
placebo pills are regarded to be in the control group. The multivariate covariates Wi are age
and gender. Each subject also underwent pretreatment brain scans, via both anatomical magnetic
resonance imaging (MRI) and resting state functional MRI (rsfMRI). Using the FMRIB Software
Library v6.0 (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki), we preprocessed the rsfMRI scans of
each subject, registered them to template MNI152 through his/her anatomical MRI scan, and then
downsampled each registered rsfMRI scan to the spatial resolution of voxel size 4mm3. Finally,
inspired by Te´treault et al. (2016), we obtained a connectivity network/matrix for each subject
which contains the Pearson correlation of the brain signals from every pair of voxels, and we treated
this network as a functional covariate Xi. Since each voxel is indexed by a three-dimensional spatial
coordinate, the functional covariate is six-dimensional.
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Table 8: The same as Table 7 except for the WOMAC score.
τˆ SE [2.5% , 97.5%]
HT
GFPLM -8.41 11.23 [-26.25 , 5.35]
CBPS -7.63 4.79 [-16.22 , 2.08]
KBCB 1.16 4.18 [-7.54 , 8.45]
Ha´jek
GFPLM -3.18 4.72 [-11.66 , 6.50]
CBPS -2.85 4.31 [-10.56 , 6.52]
KBCB 1.05 4.17 [-7.76 , 8.50]
We considered three methods for propensity score estimation, GFPLM, CBPS and KBCB. GFPLM
refers to the direct modeling method where the propensity score is estimated by fitting the model
in Remark 1.2. The top L FPC scores of Xi, denoted by Ai = (Ai1, . . . , AiL)
⊤, were used in the
approximate model (3) for GFPLM. They were also used as the multivariate substitute of Xi to
define the substitute propensity score as in (6) to perform CBPS and KBCB. To apply CBPS, (8)
was assumed for the substitute propensity score, and only the first moments of Ci = (W
⊤
i
,A⊤
i
)⊤
were balanced due to a small sample size. We used L = 4 in all three methods, which was selected
as the smallest integer such that the corresponding AIC value no longer decreases when the top
FPC scores are sequentially added to (3).
For each propensity score estimation and each pain relief measure, i.e., VAS or WOMAC score,
we obtained its corresponding HT and Ha´jek estimates for the average treatment effect of duloxitine.
We used 1, 000 bootstrap samples to provide uncertainty measures, including standard errors and
confidence intervals.
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Figure 1: Violin plots for the 1,000 bootstrap HT and Ha´jek estimates for the average treatment effect of
duloxitine on the VAS score.
HT Hájek
GFPLM CBPS KBCB GFPLM CBPS KBCB
−50
−25
0
25
Figure 2: The same as Figure 1 except for the WOMAC score.
Tables 7 and 8 provide the HT and Ha´jek estimates, bootstrap standard errors and 95% boot-
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strap percentile confidence intervals for the average treatment effect of duloxitine on VAS and
WOMAC scores respectively. They indicate no significant treatment effect of duloxitine over
placebo pills on pain relief. This is consistent with Te´treault et al. (2016), although their conclusion
was made from a double-blind clinical trial, i.e., the second trial, while we based our finding on an
observational dataset. Explicitly, the 95% confidence intervals for the average treatment effect of
duloxitine on VAS and WOMAC scores obtained from the double-blind trial are [−8.402, 6.760] and
[−9.717, 8.832] respectively. Both confidence intervals are based on t statistics assuming normality
of each treatment or control group and equal variances of the two groups, which are validated by
the Shapiro-Wilk tests and F-tests respectively.
The 1, 000 bootstrap HT and Ha´jek average treatment effect estimates are illustrated in Figures
1 and 2 for VAS and WOMAC scores respectively. Both figures show that the HT estimates based
on GFPLM for propensity score estimation have a much larger variation than the two covariate
balancing methods, but inverse propensity score weighting can substantially reduce their differences
as revealed by the Ha´jek estimates. The median of the Ha´jek estimates is shifted towards zero
compared to that of the HT estimates when the propensity score is estimated by either GFPLM or
CBPS. The two average treatment effect estimates essentially show no difference for KBCB.
6 Discussion
To the best of our knowledge, this paper has made the first attempt to study average treat-
ment effect estimation via propensity score weighting for functional data in observational studies.
The paper introduces both direct modeling and covariate balancing methods for propensity score
estimation and systematically evaluates their performances via a simulation experiment and a real
data application. The results confirm the benefits of both inverse propensity score weighting and
covariate balancing methods as advocated for multivariate data.
The methods introduced in this paper for average treatment effect estimation only focus on the
scenario where the outcome is a continuous scalar variable and there is only one functional covariate.
However, with straightforward modifications, they may be generalized to handle multiple functional
covariates and continuous functional outcomes.
The covariate balancing methods introduced above rely on a satisfactory multivariate substitute
for the functional covariate, which requires the functional covariate to be either fully observed or
densely measured (e.g., Dauxois et al., 1982; Hall and Hosseini-Nasab, 2006; Hall et al., 2006). A
future research topic is to develop covariate balancing methods for sparsely measured functional
covariates (e.g, James et al., 2000; Yao et al., 2005) or a unified approach for all types of functional
covariates (e.g., Li and Hsing, 2010; Liebl, 2019; Zhang and Wang, 2016). Another interesting
direction is to study non-truncation regularization methods, e.g., the roughness penalization, to
solve covariate balancing equations with functional covariates.
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